Jo Robson's Outputs (12)

ANCA associated vasculitis subtypes: Response (response to letter) (2022)
Journal Article

Many thanks for the opportunity to respond to the interesting letter to the Editor from Merkel, Jayne, and Bekker, with regard to our publication “ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives”.1

In the management se... Read More about ANCA associated vasculitis subtypes: Response (response to letter).

Reply - October 2022 (2022)
Journal Article

Drs. Yazici and Yazici question a specific aspect of the methodology used to develop and validate the 2022 ACR/EULAR classification criteria for ANCA-associated vasculitides. They state concerns with the fact that patients recruited into the Diagnost... Read More about Reply - October 2022.

Comment on: Benchmarking tocilizumab use for giant cell arteritis (2022)
Journal Article

It is with great interest we read the editorial on tocilizumab (TCZ) use in giant cell arteritis (GCA) published on 9th May, 2022 by Conway et al [1]. We write to share some of our data to add weight to the views expressed, particularly in relation t... Read More about Comment on: Benchmarking tocilizumab use for giant cell arteritis.

CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study (2022)
Presentation / Conference Contribution

P289 The effectiveness of interventions to reduce psychological distress in patients with autoimmune rheumatic conditions: A systematic review of effectiveness (2022)
Journal Article

Background/Aims
Autoimmune rheumatic conditions are multisystem chronic disorders associated with increased psychological distress. Consequences include poor medication adherence and high levels of disease activity. Psychological interventions may r... Read More about P289 The effectiveness of interventions to reduce psychological distress in patients with autoimmune rheumatic conditions: A systematic review of effectiveness.

P301 Patient reported outcome measure for giant cell arteritis: Clinical testing (2022)
Presentation / Conference Contribution

Background/Aims
Giant cell arteritis (GCA) presents in people over 50, with headaches, visual involvement and large vessel vasculitis. A 30-item GCA-specific patient reported outcome measure (GCA PRO) was developed and tested in a clinical setting t... Read More about P301 Patient reported outcome measure for giant cell arteritis: Clinical testing.

OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study (2022)
Presentation / Conference Contribution

2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for granulomatosis with polyangiitis (2022)
Journal Article

Objective: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA).
Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases:... Read More about 2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for granulomatosis with polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis (2022)
Journal Article

Objective To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA).

Methods Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in... Read More about 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis (2022)
Journal Article

OBJECTIVE: To develop and validate classification criteria for microscopic polyangiitis (MPA). METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identificatio... Read More about 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis (2022)
Journal Article

Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in... Read More about 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis.

2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for microscopic polyangiitis (2022)
Journal Article

ABSTRACT
Objective: To develop and validate classification criteria for microscopic polyangiitis (MPA).
Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: i) Id... Read More about 2022 American College of Rheumatology/European Alliance of Associations for rheumatology classification criteria for microscopic polyangiitis.